转移性前列腺癌治疗中化疗的当前趋势
Current Trends in Chemotherapy in the Treatment of Metastatic Prostate Cancer.
作者信息
Zhao Janice, Guercio Brendan J, Sahasrabudhe Deepak
机构信息
James P. Wilmot Cancer Institute, University of Rochester, Rochester, NY 14642, USA.
出版信息
Cancers (Basel). 2023 Aug 4;15(15):3969. doi: 10.3390/cancers15153969.
Abstract
Prostate cancer is the second most common cancer among men. Despite advances in diagnosis and management, prostate cancer led to more than 300,000 deaths globally in 2020. Chemotherapy is a cornerstone of therapy for advanced prostate cancer and can prolong survival of patients with both castration-sensitive and castration-resistant disease. Herein, we present a comprehensive review of the data supporting implementation of chemotherapy in the modern treatment of advanced prostate cancer, with special attention to the use of chemotherapy for aggressive variant prostate cancer (e.g., neuroendocrine prostate cancer) and the combination of chemotherapy with androgen signaling inhibitors. As the field of prostate cancer research continues to rapidly evolve yielding novel agents and treatment modalities, chemotherapy continues to play an essential role in prolonging the survival of patients with advanced and metastatic prostate cancer.
摘要
前列腺癌是男性中第二常见的癌症。尽管在诊断和治疗方面取得了进展，但2020年前列腺癌在全球导致了超过30万例死亡。化疗是晚期前列腺癌治疗的基石，可延长去势敏感性和去势抵抗性疾病患者的生存期。在此，我们全面综述了支持在晚期前列腺癌现代治疗中实施化疗的数据，特别关注化疗在侵袭性变异型前列腺癌（如神经内分泌前列腺癌）中的应用以及化疗与雄激素信号抑制剂的联合应用。随着前列腺癌研究领域不断快速发展，产生了新型药物和治疗方式，化疗在延长晚期和转移性前列腺癌患者的生存期方面继续发挥着重要作用。
相似文献
1
Current Trends in Chemotherapy in the Treatment of Metastatic Prostate Cancer.转移性前列腺癌治疗中化疗的当前趋势
Cancers (Basel). 2023 Aug 4;15(15):3969. doi: 10.3390/cancers15153969.
2
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.卡巴他赛联合考比司他和泼尼松与单独卡巴他赛和泼尼松治疗多西他赛治疗后转移性去势抵抗性前列腺癌患者（AFFINITY）：一项随机、开放标签、国际、3 期临床试验。
Lancet Oncol. 2017 Nov;18(11):1532-1542. doi: 10.1016/S1470-2045(17)30605-8. Epub 2017 Oct 9.
3
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.多西他赛治疗后进展的转移性去势抵抗性前列腺癌患者中，泼尼松联合卡巴他赛或米托蒽醌治疗的随机开放标签试验。
Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.
4
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分：晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.
5
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.治疗转移性去势抵抗性前列腺癌患者：现有疗法的全面综述
J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Epub 2015 Jul 18.
6
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.局部晚期和转移性前列腺癌的系统治疗进展：精准肿瘤学时代下转移性去势抵抗性前列腺癌的管理。
Eur Urol. 2019 Jan;75(1):88-99. doi: 10.1016/j.eururo.2018.03.028. Epub 2018 Apr 16.
7
Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.系统治疗对有内脏转移的前列腺癌患者的疗效：系统评价、荟萃分析和网络荟萃分析。
J Urol. 2023 Sep;210(3):416-429. doi: 10.1097/JU.0000000000003594. Epub 2023 Jun 20.
8
Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial.转移性去势抵抗性前列腺癌一线化疗中卡巴他赛与多西他赛的患者偏好：CABADOC 试验。
Eur Urol. 2022 Mar;81(3):234-240. doi: 10.1016/j.eururo.2021.10.016. Epub 2021 Nov 14.
9
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.EAU-ESTRO-SIOG 前列腺癌诊治指南。第二部分：复发、转移和去势抵抗性前列腺癌的治疗。
Eur Urol. 2017 Apr;71(4):630-642. doi: 10.1016/j.eururo.2016.08.002. Epub 2016 Aug 31.
10
[Advanced prostate cancer: sequence of androgen receptor-targeted substances and chemotherapy determines long-term survival].[晚期前列腺癌：雄激素受体靶向药物与化疗的顺序决定长期生存]
Urologe A. 2021 Feb;60(2):212-221. doi: 10.1007/s00120-020-01411-6. Epub 2020 Dec 21.
引用本文的文献
1
The prognostic value of elimination rate constant K score of prostate-specific antigen in metastatic castration-resistant prostate cancer patients treated with docetaxel.多西他赛治疗的转移性去势抵抗性前列腺癌患者中前列腺特异性抗原消除率常数K评分的预后价值
Prostate Int. 2025 Jun;13(2):103-106. doi: 10.1016/j.prnil.2024.11.007. Epub 2024 Nov 30.
2
Overdiagnosis and Overtreatment in Prostate Cancer.前列腺癌的过度诊断与过度治疗
Diseases. 2025 May 24;13(6):167. doi: 10.3390/diseases13060167.
3
Current Evidence on Cabazitaxel for Prostate Cancer Therapy: A Narrative Review.卡巴他赛用于前列腺癌治疗的当前证据：一项叙述性综述
Int J Urol. 2025 May;32(5):475-487. doi: 10.1111/iju.70019. Epub 2025 Feb 25.
4
Innovations and Emerging Trends in Prostate Cancer Management: A Literature Review.前列腺癌管理的创新与新趋势：文献综述
Cureus. 2024 Nov 6;16(11):e73128. doi: 10.7759/cureus.73128. eCollection 2024 Nov.
5
Model-Informed Radiopharmaceutical Therapy Optimization: A Study on the Impact of PBPK Model Parameters on Physical, Biological, and Statistical Measures in Lu-PSMA Therapy.模型指导的放射性药物治疗优化：关于PBPK模型参数对Lu-PSMA治疗中物理、生物学和统计学指标影响的研究
Cancers (Basel). 2024 Sep 10;16(18):3120. doi: 10.3390/cancers16183120.
6
CircBIRC6 affects prostate cancer progression by regulating miR-574-5p and DNAJB1.环状 RNA BIRC6 通过调控 miR-574-5p 和 DNAJB1 影响前列腺癌的进展。
Cancer Biol Ther. 2024 Dec 31;25(1):2399363. doi: 10.1080/15384047.2024.2399363. Epub 2024 Sep 11.
7
The role of lncRNA NEAT1 in human cancer chemoresistance.长链非编码RNA NEAT1在人类癌症化疗耐药中的作用。
Cancer Cell Int. 2024 Jul 5;24(1):236. doi: 10.1186/s12935-024-03426-x.
8
Elevating theranostics: The emergence and promise of radiopharmaceutical cell-targeting heterodimers in human cancers.提升诊疗一体化：放射性药物细胞靶向异二聚体在人类癌症中的出现与前景
iRadiology. 2024 Apr;2(2):128-155. doi: 10.1002/ird3.62. Epub 2024 Apr 6.
9
Maximum tolerated dose and toxicity evaluation of orally administered docetaxel granule in mice.多西他赛颗粒口服给药在小鼠中的最大耐受剂量及毒性评价
Toxicol Rep. 2024 Apr 5;12:430-435. doi: 10.1016/j.toxrep.2024.04.001. eCollection 2024 Jun.
10
Transferrin-Bearing, Zein-Based Hybrid Lipid Nanoparticles for Drug and Gene Delivery to Prostate Cancer Cells.用于将药物和基因递送至前列腺癌细胞的载转铁蛋白、基于玉米醇溶蛋白的杂化脂质纳米颗粒
Pharmaceutics. 2023 Nov 20;15(11):2643. doi: 10.3390/pharmaceutics15112643.
本文引用的文献
1
Coping Mechanisms for Financial Toxicity Among Patients With Metastatic Prostate Cancer: A Survey-based Assessment.转移性前列腺癌患者的财务毒性应对机制：基于调查的评估。
J Urol. 2023 Aug;210(2):290-298. doi: 10.1097/JU.0000000000003506. Epub 2023 Jul 7.
2
Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023).《晚期前列腺癌更新：AUA/SUO 指南（2023）》。
J Urol. 2023 Jun;209(6):1082-1090. doi: 10.1097/JU.0000000000003452. Epub 2023 Apr 25.
3
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.睾酮抑制联合恩扎卢胺与睾酮抑制联合标准抗雄激素治疗转移性激素敏感性前列腺癌（ENZAMET）：一项国际、开放标签、随机、III 期临床试验。
Lancet Oncol. 2023 Apr;24(4):323-334. doi: 10.1016/S1470-2045(23)00063-3.
4
First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis.转移性去势敏感型前列腺癌的一线系统治疗选择：一项实时系统评价和网络荟萃分析。
JAMA Oncol. 2023 May 1;9(5):635-645. doi: 10.1001/jamaoncol.2022.7762.
5
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.在 III 期 ARASENS 试验中，根据疾病体积和风险亚组，达罗他胺联合雄激素剥夺治疗和多西他赛治疗转移性激素敏感性前列腺癌。
J Clin Oncol. 2023 Jul 10;41(20):3595-3607. doi: 10.1200/JCO.23.00041. Epub 2023 Feb 16.
6
Individual risk prediction of high grade prostate cancer based on the combination between total prostate-specific antigen (PSA) and free to total PSA ratio.基于总前列腺特异性抗原（PSA）和游离 PSA 与总 PSA 比值的联合，对高级别前列腺癌进行个体风险预测。
Clin Chem Lab Med. 2023 Jan 27;61(7):1327-1334. doi: 10.1515/cclm-2023-0008. Print 2023 Jun 27.
7
Cancer statistics, 2023.癌症统计数据，2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
8
Out-of-Pocket Cost Burden Associated With Contemporary Management of Advanced Prostate Cancer Among Commercially Insured Patients.商业保险患者中晚期前列腺癌当代治疗的自付费用负担
J Urol. 2022 Nov;208(5):987-996. doi: 10.1097/JU.0000000000002856. Epub 2022 Sep 12.
9
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.阿比特龙联合泼尼松加至去势治疗和多西他赛用于初治转移性去势敏感性前列腺癌（PEACE-1）：一项采用2×2析因设计的多中心、开放标签、随机3期研究。
Lancet. 2022 Apr 30;399(10336):1695-1707. doi: 10.1016/S0140-6736(22)00367-1. Epub 2022 Apr 8.
10
Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019.前列腺癌发病率和死亡率：2000 年至 2019 年 89 个国家的全球状况和时间趋势。
Front Public Health. 2022 Feb 16;10:811044. doi: 10.3389/fpubh.2022.811044. eCollection 2022.
Zotero 插件